Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90033


Purpose:

To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.


Criteria:

Inclusion Criteria Concurrent Medication: Allowed: - Topical antifungal therapy. Patient must have: - Newly diagnosed clinical and histological hairy leukoplakia. - Positive HIV antibody by licensed ELISA or Western blot. Exclusion Criteria Co-existing Condition: Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded. Concurrent Medication: Excluded within 2 weeks of study entry: - Systemic antifungal treatment. - Excluded within 6 weeks of study entry: - Immunomodulators. - Systemic antiviral treatment. Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded. Prior Medication: Excluded within 2 weeks of study entry: - Systemic antifungal. - Excluded within 6 weeks of study entry: - Immunomodulators. - Systemic antiviral treatment. - Excluded within 8 weeks of study entry: - Zidovudine (AZT) or other antiretroviral therapy.


NCT ID:

NCT00002026


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Los Angeles, California 90033
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 20, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.